The Quiet Economics of a Natural Monopoly
Carbacid Investments: The Natural Monopoly Behind One of the NSE’s Quietest Fortresses
Carbacid Investments is easy to overlook. It is not a high-growth technology company, its core business is relatively simple, and its share price rarely attracts the excitement associated with Kenya’s largest listed companies. Yet beneath the seemingly boring business lies one of the more unusual competitive positions on the Nairobi Securities Exchange: a regional carbon dioxide business built around a natural resource that competitors cannot easily replicate.
The investment case becomes even more compelling when Carbacid is compared with BOC Kenya. Both operate in industrial gases, both have long-established positions in East Africa, and both possess strong balance sheets. But their moats are fundamentally different. BOC’s advantage comes from technical expertise, regulation, customer relationships and the infrastructure required to supply critical medical gases. Carbacid’s advantage begins much deeper — literally — with the geology beneath Kereita Forest.
The moat starts underground
Most industrial-gas companies have to manufacture or process their products using energy-intensive processes or chemical by-products. Carbacid has a different starting point. It extracts naturally occurring CO₂ from underground reservoirs and primarily needs to purify it before selling it to customers.
That distinction matters enormously economically. The company is effectively sitting on a natural source of its most important raw material. Research comparing the two businesses estimates Carbacid’s gross margins at roughly 64%, compared with the structurally higher costs faced by producers that have to manufacture CO₂.
This creates what can be described as a geological moat. A competitor can build a factory, purchase equipment, hire engineers and replicate a distribution network. It cannot simply replicate Carbacid’s underground reservoir.
This is also why the threat from technologies such as direct-air capture needs to be viewed carefully. Direct-air-capture companies may eventually become important players in carbon removal, but they are solving a different problem and selling to different customers. Carbacid sells physical, food-grade CO₂ to beverage, food and industrial customers, whereas carbon-removal companies are effectively monetising the removal and storage of CO₂. The economics are therefore very different.
The more relevant competitive threat is not futuristic carbon-removal technology. It is cheaper alternative CO₂ supply, particularly geothermal by-product recovery, and customers increasingly producing their own CO₂.
The surprising weakness: customers have power too
A monopoly does not automatically mean unlimited pricing power.
Carbacid has an important vulnerability in the structure of its customer base. Its largest customers include major beverage manufacturers and breweries, meaning that a relatively small number of sophisticated corporate buyers account for a meaningful portion of demand. These customers are large enough to invest in their own production and recovery systems.
EABL provides perhaps the clearest illustration. Its investment in CO₂ recovery allows it to capture gas generated during fermentation and reuse it, reducing its dependence on external suppliers. This is a genuine threat because the strongest customer relationships are not necessarily the strongest competitive barriers if customers can economically integrate backwards into the supply chain.
This creates an interesting balance of power. Carbacid has an enormous cost advantage over many potential suppliers, but its largest customers possess significant bargaining power because of their scale and technical capabilities.
The company therefore cannot simply rely on monopoly status. It needs to remain the most economical and reliable external source of CO₂.
Its response has been sensible: expand geographically and broaden the range of applications for its gas. Export markets now account for roughly half of revenue, while Carbacid is targeting applications ranging from welding and fire extinguishers to grain-silo treatment and cold-chain refrigeration.
That diversification is strategically important. The more customers, industries and countries Carbacid serves, the less vulnerable it becomes to the purchasing decisions of any individual anchor customer.
Supplier power is where Carbacid really stands out
If customer concentration is one of Carbacid's weaknesses, supplier power is arguably one of its greatest strengths.
The company does not depend on an external producer for the fundamental raw material underpinning its business. Its competitive advantage comes from controlling access to a naturally occurring CO₂ resource. This is fundamentally different from a conventional manufacturer whose margins can be squeezed by rising raw-material prices.
That helps explain why Carbacid has historically been able to generate exceptionally high margins and why its cost position is difficult for conventional competitors to challenge.
It also changes the nature of inflation risk. Carbacid is not immune to inflation — administrative, energy, logistics and distribution costs can still rise — but the company begins with a fundamentally advantageous cost of production.
The threat therefore comes less from suppliers raising the price of inputs and more from competitors finding alternative ways of supplying the customer.
Distribution is the second moat
Owning the resource is only half the story. Carbacid has also built the infrastructure necessary to move the product.
Its specialized high-pressure tanker fleet and regional distribution network create another barrier to entry. Supplying industrial CO₂ is not simply a matter of producing the gas at the cheapest possible price; it also requires reliable transportation and the ability to deliver safely to customer facilities across borders.
Carbacid has expanded its reach beyond Kenya into Uganda, Tanzania, Rwanda, Burundi, Zambia and other African markets. Research estimates that its regional market share exceeds 65%.
This creates a useful combination: resource advantage plus distribution advantage.
A potential competitor therefore faces two problems. It must find or manufacture CO₂ economically, and then it must build the logistical network required to compete with an incumbent that has spent decades establishing customer relationships and delivery infrastructure.
BOC reveals just how unusual Carbacid's moat is
The comparison with BOC Kenya makes this distinction clearer.
BOC has a very strong business. Its medical-gas franchise benefits from regulation, technical expertise, brand trust and high switching costs. Hospitals cannot casually change suppliers of critical medical gases, particularly where infrastructure and certification are involved. BOC also benefits from the technology and expertise of its parent, Linde.
But BOC's moat requires continual operational execution.
Carbacid's advantage is more structural. Its principal source of differentiation is a natural resource that cannot be recreated through capital expenditure. That is why our comparative research describes Carbacid's moat as having very high durability, while BOC's remains strong but vulnerable to developments such as hospitals installing their own oxygen-generation plants.
In simple terms, BOC has a technical fortress. Carbacid has a geological fortress.
That does not necessarily make Carbacid the better company in every respect. But it does make its competitive advantage unusually difficult to replicate.
The balance sheet adds another layer to the moat
Perhaps the most underappreciated part of the Carbacid story is that the company is not simply a natural-resource business. It is also an investment company. This produces an unusual “double moat.” The operating business generates cash, while the accumulated financial assets provide an additional buffer against operating weakness.
Carbacid's liquid assets sits at roughly KSh2.4 billion across cash, bonds and equities, with zero long-term debt. Total assets were approximately KSh6 billion.
Carbacid does not need to depend heavily on banks to fund expansion. It can finance capital expenditure internally, withstand periods of weaker demand, invest in regional expansion and continue returning capital to shareholders without putting significant pressure on the balance sheet. This is particularly valuable in a cyclical or inflationary environment. A highly leveraged competitor may be forced to raise prices, cut investment or refinance debt at precisely the wrong time. Carbacid has considerably more room to absorb shocks.
It also explains why the company has such a remarkable earnings record. Carbacid has not recorded a loss since 1989 and reached its first KSh1 billion annual net profit in FY2025.
But investors should not confuse resilience with growth
This is where the Carbacid thesis becomes more nuanced.
The company is exceptionally defensive, but its recent earnings growth does not entirely reflect stronger underlying operating performance. In H1 2026, net profit increased 6.9% to KSh465 million, while operating profit actually declined 2.2%. The improvement in reported earnings was driven largely by gains on the company's investment portfolio.
That distinction matters. An investor buying Carbacid is effectively buying two businesses: a high-margin CO₂ operation and an investment portfolio. The latter can provide substantial support when markets are performing well, but investment gains are inherently less predictable than operating profits.
There is therefore a risk that investors mistake balance-sheet strength and fair-value gains for accelerating underlying business growth.
The core business remains the more important long-term variable.
The real question is whether the moat survives
The Carbacid investment thesis ultimately comes down to one question: can the company preserve its structural cost advantage while preventing customers and new suppliers from eroding its market position?
There are three developments worth watching closely.
The first is customer self-sufficiency. If large beverage companies increasingly recover their own CO₂, Carbacid's addressable external market could shrink.
The second is alternative supply. Geothermal CO₂ recovery is potentially more relevant than direct-air capture because geothermal CO₂ could emerge as a low-cost industrial by-product. This is a potential threat to Carbacid's pricing position.
The third is whether regional expansion can compensate for slower Kenyan growth. Carbacid's move into markets such as Uganda, Tanzania and Southern Africa potentially expands its addressable market, but it also introduces foreign-exchange risk and greater logistical complexity.
These are not reasons to dismiss the thesis. They are the variables that determine whether the moat remains economically valuable.
The investment takeaway
Carbacid's appeal is not that it is a spectacular growth story. It is that several favourable characteristics reinforce one another.
It owns access to a scarce natural resource. That resource gives it a structural cost advantage. It has built a regional distribution network around that advantage. Its customers depend on reliable, high-purity supply, creating meaningful switching and relationship benefits. And the company has accumulated enough financial assets to make its balance sheet look more like an investment fund than a conventional industrial manufacturer.
The comparison with BOC highlights the distinction. BOC is an excellent example of a business protected by technical expertise, regulation and switching costs. Carbacid goes one step further by adding a natural-resource advantage and an unusually powerful balance sheet.
But the moat is not invincible. Customer backward integration, geothermal CO₂ production, synthetic alternatives and regional currency movements could gradually reduce the economics of the franchise.
That is ultimately what makes Carbacid interesting as an investment. The question is not whether it has a moat — the evidence strongly suggests that it does. The more important question is whether the market is pricing that moat appropriately, particularly when the underlying operating business is growing slowly.
For an investor willing to sacrifice excitement for durability, Carbacid's combination of natural monopoly economics, financial strength and regional expansion makes it one of the more distinctive defensive franchises on the NSE.
Comments